

Sabinsa's Lactospore receives positive response

09 January 2019 | News

A recent peer-reviewed study reported the results of an investigation into the functional aspects of Sabinsa's shelf stable probiotic *Bacillus coagulans* MTCC 5856, known worldwide as Lactospore®, including survival during simulated digestion. The study, *Probiotic Bacillus coagulans* MTCC 5856 spores exhibit excellent in-vitro functional efficacy in simulated gastric survival, mucosal adhesion and immunomodulation, was published in the *Journal of Functional Foods* (2019 Jan; 52: 100-108).



The authors noted that Lactospore showed remarkable immunomodulatory and anti-inflammatory activity under co-treatment relative to post-treatment condition.

A recent peer-reviewed study reported the results of an investigation into the functional aspects of Sabinsa's shelf stable probiotic *Bacillus coagulans* MTCC 5856, known worldwide as Lactospore®, including survival during simulated digestion. The study, *Probiotic Bacillus coagulans* MTCC 5856 spores exhibit excellent in-vitro functional efficacy in simulated gastric survival, mucosal adhesion and immunomodulation, was published in the *Journal of Functional Foods* (2019 Jan; 52: 100-108).

This independent study conducted by university researchers reported that Lactospore showed remarkable ability to survive (92%) gastric and intestinal conditions and then to colonize the intestine by effectively adhering to the colonic epithelium.

Furthermore, this study also reported that Lactospore at a dose of 2×10^9 cfu/ml did not show any cytotoxic effects towards HT-29 or LS174T cells, adding to the scientific evidence of safety previously demonstrated by several clinical trials.

Lactospore exhibited excellent immunomodulatory efficacy by down regulating the secretion of the IL-8 (key pro-inflammatory cytokine) while concomitantly promoting increased secretion of IL-10 (anti-inflammatory cytokine).

The authors also noted that Lactospore showed remarkable immunomodulatory and anti-inflammatory activity under co-treatment relative to post-treatment condition suggesting significance of early application in order to suppress inflammation and support its incorporation into functional foods for improved gut health.

"The prominent survival during digestion, adhesion capacity and remarkable immunomodulatory potential of Lactospore, coupled with its known ability to survive the food processing conditions and storage, supports its incorporation into shelf stable food products targeted at improving and/or treating gut health," said Sami-Sabinsa founder Dr. Muhammed Majeed.

LactoSpore is Sabinsa's clinically validated and commercial probiotic preparation containing L (+) lactic acid producing microbial preparation from *Bacillus coagulans* MTCC 5856. Sabinsa offers LactoSpore at various strengths: 6 billion, 15 billion and 100 billion spores/g. The health benefits and stability of LactoSpore have been published in multiple peer-reviewed journals, and the present investigation further supports the functional benefits of this branded probiotic in human health.